News & Presentations
Wilsons Updated Research Report
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains...
ShareCafe Webinar 29 April 2022
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company...
NailMail Q1 2022
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include:...
Investor Webinar April 2022
Thank you to those that attended our Investor Webinar today, 5 April 2022 at 9:00 AM AEST. Hexima Chief Operating Officer, Dr Nicole van der...
Presentation at American Academy of Dermatology March 2022
Pezadeftide Mode of Action Hexima is proud to present new data describing the unique mechanism of action of pezadeftide as a potent antifungal...
Wilsons Research Report
Recently WILSONS published its initiation research report on Hexima Limited (ASX:HXL) with an OVERWEIGHT rating and a $0.75 12-month price target....
NailMail Q4 2021
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 December 2021. Achievements for the quarter include:...
Hexima featured at Edison Global Healthcare 2022
Hexima was pleased to be featured at Edison Open House: Global Healthcare 2022. Edison Group is an investment research, investor relations and...
Phil Rose appointed Chief Commercial Officer
Hexima announces the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing...
Nancy Sacco appointed Chief Development Officer
Hexima announces the appointment of Dr Nancy Sacco, PhD as Chief Development Officer. Dr Sacco will report to Michael Aldridge, Managing Director...
Annual General Meeting 2021
The Hexima Limited Annual General meeting was held on 2 December 2021 at 11am. A copy of the CEO presentation and a recording of the meeting are...
The Market Herald Interview
Hexima's CEO, Mr Michael Aldridge spoke to Sonia Madigan on The Deal Room by The Market Herald regarding its recent capital raise and what to expect...
Completion of $10 Million Institutional Placement
Hexima is pleased to announce that it has completed the bookbuild for a placement to raise $10.0 million. In addition, Hexima proposes to launch a...
NailMail Q3 2021
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 30 September 2021. Major achievements covered in this...
KOL Interviews
Hexima recently took the opportunity to speak with some of the members of its Scientific Advisory Board about Onychomycosis: the disease, its...
Hexima Presenting at AusBiotech
Mr Michael Aldridge, CEO of Hexima, presented today at AusBiotech’s “Australia Biotech Invest & Partnering Conference 2021”. AusBiotech is the...
Review of FY21 – Investor Webinar
Watch Hexima's CEO, Mr Michael Aldridge, review the achievements of FY21 and inform investors of expected important developments and milestones....
Consumer Centric Investor Webinar
Watch Hexima CEO, Mr Michael Aldridge, and Hexima's Commercial Consultant, Mr Phil Rose, discuss how Hexima is taking a consumer-centric view on...
Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar
Joining the annual APMA 2021 Annual Scientific Meeting held from July 29 to August 1, was an important opportunity to share Hexima’s data on...
NailMail Q2 2021
Hexima Limited (ASX:HXL) is proud to release its “NailMail” quarterly activities report for the quarter ended 30 June 2021. Major achievements...